Nanoparticle immune treatment for SHH‑subtype medulloblastoma
Nanoformulated small molecule immunotherapy for SHH medulloblastoma
This project tests a tiny‑particle version of an immune drug designed to help children with SHH‑subtype medulloblastoma live longer with fewer lifelong side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11251558 on NIH RePORTER |
What this research studies
The team is creating a nanoparticle formulation of an immune‑stimulating drug (resiquimod) to help it reach brain tumors and activate tumor‑associated immune cells in SHH medulloblastoma. The particles are designed to cross the blood–brain barrier and deliver the drug to TAMs that express TLR7/8. Researchers will test delivery, immune activation, and anti‑tumor effects in laboratory and model systems and explore combining the drug with cancer vaccines. The overall aim is to develop a safer, more effective immune approach to reduce toxic standard therapies for children.
Who could benefit from this research
Good fit: Children with SHH‑subtype medulloblastoma, particularly those with recurrent disease or who are candidates for experimental immune therapy, would be the most relevant participants.
Not a fit: Patients with non‑SHH medulloblastoma subtypes, other unrelated cancers, or those unable to access the study site likely would not benefit from this specific project.
Why it matters
Potential benefit: If successful, this could produce immune‑based treatments that better reach brain tumors and lower the long‑term cognitive and physical harms of current therapies for children.
How similar studies have performed: Related TLR7/8 drugs like resiquimod have been tested in clinical trials for melanoma, bladder cancer, and glioma, but a blood‑brain‑penetrant nanoparticle formulation for medulloblastoma remains novel and largely unproven in humans.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Sokolsky-Papkov, Marina — Univ of North Carolina Chapel Hill
- Study coordinator: Sokolsky-Papkov, Marina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.